About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in New York | 22,668 Studies Near You | Clareo Health

Clinical Trials LocationsNew York

Clinical Trials in New York

Discover 22,668 clinical trials near New York, New York. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 4141-4160 of 22,668 trials

RECRUITINGPhase 1< 1 mile

Study of Safety and Efficacy of RGT-61159 in Adults With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC)

NCT06462183

Phase 1 study to evaluate safety, tolerability and anti-tumor activity of RGT-61159 in patients with ACC or CRC

Adenoid Cystic CarcinomaColorectal Cancer

Rgenta Therapeutics Inc105 participantsStarted Aug 2024

Boston, Massachusetts, United States • Ann Arbor, Michigan, United States • St Louis, Missouri, United States +7 more locations

TERMINATEDPhase 1< 1 mile

Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2

NCT05980416

This study is an open-label, international, multi-center, Phase 1 study in adult patients with solid tumors likely to express CLDN18.2.

Stomach NeoplasmGastrointestinal NeoplasmsDigestive System Neoplasm+2 more

Elevation Oncology88 participantsStarted Aug 2023

Phoenix, Arizona, United States • Duarte, California, United States • New Haven, Connecticut, United States +17 more locations

Find Trials by Condition in New York

Breast Cancerin New York Lung Cancerin New York Prostate Cancerin New York Colorectal Cancerin New York Melanomain New York Leukemiain New York Lymphomain New York Pancreatic Cancerin New York Ovarian Cancerin New York Brain Cancerin New York Diabetes

Data from ClinicalTrials.govTerms

Active Not RecruitingPhase 1/2< 1 mile

Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors

NCT05275478

This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific MTAP-deleted tumor types. The study drug, TNG908, is a selective PRMT5 inhibitor administered orally. The study is planned to treat up to 192 participants.

Locally Advanced Solid Tumor

Tango Therapeutics, Inc.192 participantsStarted Mar 2022

Los Angeles, California, United States • San Francisco, California, United States • Denver, Colorado, United States +17 more locations

RECRUITING< 1 mile

A Study to Assess Growth in Children With Idiopathic Short Stature

NCT06309979

Study 111-903 will generate baseline growth data in children with ISS by collecting growth measurements and other variables of interest.

Idiopathic Short Stature

BioMarin Pharmaceutical300 participantsStarted Aug 2024

Phoenix, Arizona, United States • Los Angeles, California, United States • Los Angeles, California, United States +37 more locations

Active Not Recruiting< 1 mile

Delirium in Children Undergoing Stem Cell Transplantation

NCT04937400

Children undergoing stem cell transplants are at risk for delirium, a temporary change in thinking and behavior. This study will define delirium rates, risk factors, and outcomes. Our eventual goal is to reduce delirium in this population.

Stem Cell Transplant ComplicationsDelirium

Weill Medical College of Cornell University1,040 participantsStarted Jul 2021

San Francisco, California, United States • Boston, Massachusetts, United States • New York, New York, United States +3 more locations

COMPLETEDPhase 2/3< 1 mile

Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer

NCT02101788

This phase II/III trial studies how well trametinib works and compares it to standard treatment with either letrozole, tamoxifen, paclitaxel, pegylated liposomal doxorubicin, or topotecan in treating patients with low-grade ovarian cancer or peritoneal cavity cancer that has come back (recurrent), become worse (progressive), or spread to other parts of the body. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether trametinib is more effective than standard therapy in treating patients with ovarian or peritoneal cavity cancer.

Borderline Ovarian Serous TumorMicropapillary Serous CarcinomaOvarian Serous Adenocarcinoma+3 more

National Cancer Institute (NCI)260 participantsStarted Apr 2014

Huntsville, Alabama, United States • Anchorage, Alaska, United States • Anchorage, Alaska, United States +498 more locations

RECRUITINGPhase 1< 1 mile

Short-Term Linvoseltamab Treatment on Top of Chronic Dupilumab Treatment for Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy

NCT06369467

This study is researching an experimental drug called linvoseltamab combined with another drug called dupilumab. The study is looking at patients who have severe IgE-mediated food allergy. If the patient has an allergy, the body's defense system (immune system) overreacts to an allergen (eg, certain foods like peanuts, milk, shellfish) by making antibodies called IgE. An antibody is a protein that allows the immune system to find and fight off things the body does not recognize (allergens). IgE antibodies are sent out by cells like plasma cells. These antibodies and allergens bind to other cells that send out chemicals, causing an allergic reaction. The aim of the study is to see what side effects happen when linvoseltamab is combined with dupilumab. The study is looking at several other research questions, including: * What side effects may happen from taking the study drugs * Does linvoseltamab combined with dupilumab affect other types of antibodies in the blood at different times * How much study drug(s) is in the blood at different times

Regeneron Pharmaceuticals6 participantsStarted May 2024

Tampa, Florida, United States • Atlanta, Georgia, United States • Boston, Massachusetts, United States +4 more locations

RECRUITINGPhase 43.9 miles

DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment

NCT07158164

To prospectively evaluate the efficacy and safety of DPYD-guided dosing strategies in a real-world clinical setting, specifically by comparing the incidence of severe (Grade 3 and 4) fluoropyrimidine-related toxicities of heterozygous DPYD variant patients assigned to DPYD-guided reduced dosing versus patients with standard dosing in the control arm.

Colorectal NeoplasmsBreast NeoplasmsHead and Neck Neoplasms+1 more

Rutgers, The State University of New Jersey100 participantsStarted Aug 2025

Belleville, New Jersey, United States • Elizabeth, New Jersey, United States • Hamilton, New Jersey, United States +9 more locations

Active Not RecruitingPhase 213 miles

Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease

NCT06079190

The aim of this study is to assess the efficacy and safety of GSK4527226 in participants with early Alzheimer's Disease (AD) (including mild cognitive impairment \[MCI\] and mild dementia due to AD) of 2 dose levels of GSK4527226 compared to placebo.

Alzheimer's Disease

GlaxoSmithKline367 participantsStarted Oct 2023

San Diego, California, United States • Lake Mary, Florida, United States • Lake Worth, Florida, United States +94 more locations

TERMINATEDPhase 2/313 miles

Study of LAU-7b for the Treatment of Coronavirus Disease 2019 (COVID-19) Disease in Adults

NCT04417257

A randomized, double-blind, placebo-controlled Phase 2/3 Study of LAU-7b against confirmed COVID-19 Disease in hospitalized patients at a higher risk of complications.

COVID-19 Disease

Laurent Pharmaceuticals Inc.351 participantsStarted Aug 2020

Chandler, Arizona, United States • Newport Beach, California, United States • Sacramento, California, United States +26 more locations

Active Not RecruitingNA13 miles

M6-C Artificial Cervical Disc Two-Level IDE Pivotal Study

NCT04982835

Prospective, concurrently controlled, multi-center study to evaluate the safety and effectiveness of the Spinal Kinetics M6-C™ artificial cervical disc compared to anterior cervical discectomy and fusion (ACDF) for the treatment of contiguous two-level symptomatic cervical radiculopathy at vertebral levels from C3 to C7 with or without spinal cord compression.

Cervical Disc Degenerative Disorder

Orthofix Inc.156 participantsStarted Jul 2021

Phoenix, Arizona, United States • Beverly Hills, California, United States • Long Beach, California, United States +18 more locations

Active Not RecruitingNA13 miles

A Clinical Evaluation of the MicroSTent® PeripherAl Vascular SteNt in Subjects With Arterial Disease Below the Knee (STAND)

NCT03477604

Randomized multicenter clinical trial consisting of two arms; one arm treated with PTA plus the MicroStent® System and one arm treated with PTA alone. Purpose to evaluate the safety and effectiveness of using the MicroStent® Peripheral Vascular Stent System, hereafter referred to as the MicroStent® System, for the treatment of infrapopliteal lesions in subjects with peripheral arterial disease.

Peripheral Arterial Disease

Micro Medical Solution, Inc.177 participantsStarted Mar 2020

Birmingham, Alabama, United States • Mesa, Arizona, United States • St. Helena, California, United States +18 more locations

COMPLETEDPhase 217 miles

Study of Daratumumab in Patients With Mild to Moderate Alzheimer's Disease

NCT04070378

This is an open-label, pilot study designed to explore whether daratumumab may have a clinically meaningful effect in patients with mild to moderate Alzheimer's disease.

Alzheimer Disease

Marc L Gordon, MD16 participantsStarted Nov 2019

Manhasset, New York, United States

Active Not RecruitingPhase 326 miles

SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM

NCT05405166

This is a randomized, multicenter, Phase 3, open-label study evaluating subcutaneous (SC) vs intravenous (IV) administration of isatuximab in combination with pomalidomide and dexamethasone (Pd) in RRMM patients (study participants) who have received at least 1 prior line of therapy including lenalidomide and a proteasome inhibitor (PI). Eligible participants will be randomized 1:1 into 1 of 2 study arms: Arm SC: Isatuximab SC + Pd Arm IV: Isatuximab IV + Pd Participants will be allowed to continue therapy until disease progression, unacceptable adverse events (AEs), participant request to discontinue therapy or any other reason, whichever comes first.

Plasma Cell Myeloma Recurrent

Sanofi531 participantsStarted Jun 2022

Bullhead City, Arizona, United States • Prescott Valley, Arizona, United States • Aurora, Colorado, United States +143 more locations

Active Not Recruiting34 miles

STOP Persistent AF PAS

NCT05005949

The STOP Persistent AF Post Approval Study (PAS) is a prospective, global, multicenter, observational trial.

Persistent Atrial Fibrillation

Medtronic Cardiac Ablation Solutions400 participantsStarted Aug 2021

Hartford, Connecticut, United States • Stamford, Connecticut, United States • Clearwater, Florida, United States +14 more locations

COMPLETEDPhase 335 miles

A Study to Assess the Long-term Efficacy and Safety of AXS-12 (Reboxetine) in Subjects With Narcolepsy (ENCORE)

NCT05113745

This study will evaluate the long-term efficacy and safety of AXS-12 in narcoleptic subjects with cataplexy and excessive daytime sleepiness (EDS).

NarcolepsyCataplexyExcessive Daytime Sleepiness

Axsome Therapeutics, Inc.68 participantsStarted Oct 2021

Phoenix, Arizona, United States • Boulder, Colorado, United States • Colorado Springs, Colorado, United States +22 more locations

COMPLETED70 miles

Innovative Support for Patients With SARS-COV2 Infections (COVID-19) Registry (INSPIRE)

NCT04610515

The Innovative Support for Patients with SARS COV-2 Infections Registry (INSPIRE) study is a CDC-funded COVID-19 project to understand the long-term health outcomes in recently tested adults, both negative and positive, who have suspected COVID symptoms at the time of their test. Participants will complete short online surveys every 3 months for 18 months, share information about their health using a secure web-based platform, and are compensated for their time.

Covid19ME/CFSSARS COV2+3 more

Rush University Medical Center6,000 participantsStarted Dec 2020

Los Angeles, California, United States • San Francisco, California, United States • New Haven, Connecticut, United States +5 more locations

COMPLETEDPhase 2362 miles

A Study Investigating Long-term Treatment With Spesolimab in People With a Skin Disease Called Hidradenitis Suppurativa Who Completed a Previous Clinical Trial

NCT04876391

This study is open to adults with hidradenitis suppurativa who took part in a previous clinical study of a medicine called spesolimab. Participants who completed treatment can join this study. The purpose of this study is to find out how safe spesolimab is and whether it helps people with hidradenitis suppurativa in the long-term. Participants are in this study for about 2 years and 4 months. For 2 years, participants visit the study site every 2 weeks to get spesolimab injections under the skin. At study visits, doctors check the severity of participants' hidradenitis suppurativa and collect information on any health problems of the participants.

Hidradenitis Suppurativa

Boehringer Ingelheim45 participantsStarted Aug 2021

Los Angeles, California, United States • Indianapolis, Indiana, United States • Rochester, Minnesota, United States +23 more locations

COMPLETEDPhase 1836 miles

A Trial Evaluating TG4050 in Ovarian Carcinoma.

NCT03839524

This is a multicenter, open-label, single arm phase I study evaluating the safety and tolerability as well as some activity parameters of TG4050 in patients with ovarian, fallopian or peritoneal serous carcinoma.

Ovarian CarcinomaFallopian Tube CancerPeritoneal Carcinoma

Transgene64 participantsStarted Dec 2019

Phoenix, Arizona, United States • Jacksonville, Florida, United States • Rochester, Minnesota, United States +3 more locations

Not Yet RecruitingPhase 21016 miles

B-PaLMZ for TB Meningitis

NCT07227779

This two-stage study will compare consented research participants with tuberculous meningitis receiving BPaLMZ to controls receiving SOC of rifampicin (R), isoniazid (H), pyrazinamide (Z), and ethambutol (E), known as RHZE.

Tuberculous Meningitis

University of Minnesota240 participantsStarted Feb 2026

Minneapolis, Minnesota, United States • Kampala, Uganda

PreviousPage 208 of 1134Next

in New York

Heart Diseasein New York